Clinical Trial: Ultra-Micronized vs Liposomal PEA 600 mg: A Crossover PK Study in Healthy Subjects

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07804758) titled 'Ultra-Micronized vs Liposomal PEA 600 mg: A Crossover PK Study in Healthy Subjects' on Aug. 31.

Brief Summary: This is a crossover pharmacokinetic study comparing two oral formulations of palmitoylethanolamide (PEA) as a dietary supplement: ultra-micronized PEA 600 mg (Normast 600) and liposomal PEA 600 mg (AliaMed), in 6 healthy subjects following a single oral dose.

Eligible subjects presenting at the Crabion S.r.l. research center for routine screening, who meet the inclusion criteria and provide informed consent, will be enrolled and allocated to one of two groups using non-random, systematic alternate allocation.

On Day 1, af...